文献速递血液净化与透析

墨西哥MEXHEMO血液透析队列的死亡率与实践模式

Mortality and Practice Patterns in the MEXHEMO Hemodialysis Cohort.
PubMed 文献 · Kidney Int Rep · 2026-02-26

MEXHEMO是一项回顾性观察性队列研究,纳入墨西哥41家透析中心的11,779例维持性血液透析患者,随访6个月。粗死亡率为130/1000患者年,标化死亡比相对USRDS为1.31、相对智利登记为1.57。缺乏社保覆盖、低白蛋白血症、血红蛋白≤9 g/dl、导管使用和透析器复用与死亡独立相关。

要点

  • 墨西哥血透患者虽较年轻但死亡率仍偏高,标化死亡比高于USRDS和智利登记。
  • 缺乏社保覆盖、低白蛋白血症、血红蛋白≤9 g/dl、导管使用和透析器复用与死亡独立相关。
  • 结果提示需要建立全国透析登记并推行质量改进政策。

核心结论

  • MEXHEMO是墨西哥已报道的最大血透患者队列,尽管人群相对年轻,死亡率仍升高。

研究设计与样本

  • 回顾性观察性队列研究,邀请全国中心报告2023年1月1日至6月30日维持性血透患者数据。
  • 共纳入41家诊所的11,779例患者,随访6个月,从各中心病历确定生命状态。

主要发现

  • 患者平均年龄52±16岁,57%为男性,92%有社保覆盖。
  • 86%处方高通量血透,43%进行透析器复用。
  • 粗死亡率为130(95%CI:121-139)例/1000患者年。
  • 标化死亡比相对USRDS为1.31(95%CI:1.25-1.38),相对智利血透登记为1.57(95%CI:1.52-1.62)。
  • 缺乏社保覆盖、低白蛋白血症、血红蛋白≤9 g/dl、导管使用和透析器复用与死亡独立相关。

临床怎么用

  • 对血透患者应关注社保覆盖、白蛋白、血红蛋白、血管通路类型和透析器复用等可干预因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease represents a major public health challenge in Mexico. In the absence of a national hemodialysis (HD) registry, epidemiological data on patient characteristics, treatment practices, and outcomes remain scarce. The MEXHEMO project aims to characterize the clinical profile and outcomes of Mexican patients undergoing chronic HD. METHODS: This was a retrospective, observational cohort study. Centers nationwide were invited to report data from patients receiving maintenance HD between January 1 and June 30, 2023. Demographic, clinical, dialysis-related, and laboratory information was collected. Vital status was ascertained from medical records at each dialysis center, with 6 months of follow-up. Outcomes were mortality rates, standardized mortality ratios (SMRs), and risk factors for death. SMRs were calculated using the 2019 United States Renal Data System (USRDS) and the 2024 Chilean HD registry as reference populations. RESULTS: A total of 11,779 patients from 41 clinics were included. Mean age was 52 ± 16 years; 57% were male, and 92% had social security coverage. High-flux HD was prescribed in 86%, and 43% underwent dialyzer reuse. The crude mortality rate was 130 (95% confidence interval [CI]: 121-139) deaths/1000 patient-yrs. SMR were 1.31 (95% CI: 1.25-1.38) compared with the USRDS, and 1.57 (95% CI: 1.52-1.62) compared with the Chilean registry. Lack of social security coverage, hypoalbuminemia, hemoglobin (Hb) ≤ 9 g/dl, catheter use, and dialyzer reuse were independently associated with mortality. CONCLUSION: MEXHEMO constitutes the largest cohort of HD patients reported in Mexico. The findings highlight elevated mortality despite a relatively young population, emphasizing the need for a national registry and quality improvement policies.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ardavin-Ituarte JM, Vega-Vega O, Lopez-Gil S, et al. Mortality and Practice Patterns in the MEXHEMO Hemodialysis Cohort. Kidney Int Rep. 2026. PMID: 42006204. doi:10.1016/j.ekir.2026.106383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。